Degradable Polymer Depot Sustains Amide Release in Joints
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions for treating inflammatory diseases like osteoarthritis lack a controlled and sustained-release formulation for direct administration to joints, leading to frequent dosing and potential side effects.
Innovation Solution
A pharmaceutical depot comprising N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide or its pharmaceutically acceptable salt, combined with a degradable polymer that creates an acidic microclimate, allowing for controlled and sustained release of the active agent at the administration site.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the amide derivative is administered directly to the joint site, then the therapeutic effect is improved, but the frequency of dosing increases and side effects worsen
Solution Approach 1:
The patent employs a degradable polymer matrix that dynamically releases the amide derivative over time through controlled degradation. The polymer structure transitions from an intact carrier to degraded fragments, enabling sustained release and reducing dosing frequency while maintaining therapeutic effectiveness at the joint site.
Solution Approach 2:
The patent utilizes changes in the local chemical environment (pH) to control drug release. The amide derivative is released in response to pH changes in the joint environment, allowing the system to adapt its release rate based on local conditions without requiring external control mechanisms.
2Reliability
If the amide derivative is administered directly to the joint site, then the therapeutic effect is improved, but the severity of side effects increases
Solution Approach 1:
The patent creates a localized delivery system where the amide derivative is released specifically at the joint site through the degradable polymer matrix. This local quality approach ensures therapeutic concentrations are achieved at the target site while minimizing systemic exposure and associated side effects.
Solution Approach 2:
The degradable polymer provides continuous release of the amide derivative over an extended period, maintaining steady therapeutic levels at the joint site. This continuous action reduces peak concentration spikes that would otherwise cause severe side effects, while ensuring sustained therapeutic effect.
3Loss of time
If a controlled-release formulation is used, then the frequency of dosing is reduced, but the manufacturing complexity increases
Solution Approach 1:
The patent employs a degradable polymer matrix that is designed to be consumed during the release process. The polymer is relatively simple in structure compared to complex controlled-release devices, and its degradation products are metabolized or excreted, eliminating the need for complex retrieval or disposal mechanisms.
Solution Approach 2:
The degradable polymer matrix self-regulates the release process through its own degradation, eliminating the need for external control mechanisms such as pumps, sensors, or actuation systems. This self-service approach significantly simplifies manufacturing while achieving controlled release.
4Productivity
If the polymer degrades to create an acidic microclimate, then the release of the active agent is enhanced, but the stability of the active agent may be compromised
Solution Approach 1:
The patent converts the potentially harmful effect of acid degradation on drug stability into a beneficial release mechanism. The acidic microclimate created by polymer degradation, which would normally compromise drug stability, is instead harnessed to trigger controlled release of the amide derivative, enhancing productivity while the drug's structural features protect it from complete degradation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The depot provides a therapeutically effective, sustained release of the active agent at the joint, reducing frequency of dosing and severity of side effects, while maintaining a high local concentration for extended periods, thus effectively treating inflammatory diseases like osteoarthritis.
Implementation Method 1
a polymer which degrades to create an acidic microclimate
Data Source
AI summary
A pharmaceutical depot comprising (i) N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof, as a pharmaceutical agent (PA) and (ii) a polymer which degrades to create an acidic microclimate, wherein the PA is released from the polymer upon polymer degradation.